Sevoflurane suppresses proliferation by upregulating microRNA-203 in breast cancer cells

JIAYING LIU\(^1\), LONGQIU YANG\(^2\), XIA GUO\(^3\), GUANGLI JIN\(^4\), QIMIN WANG\(^4\), DONGDONG LV\(^4\), JUNLI LIU\(^1\), QIU CHEN\(^4\), QIONG SONG\(^4\) and BAOLIN LI\(^4\)

\(^1\)Department of Anesthesiology, The Second Clinical College of Zhengzhou University, Zhengzhou, Henan 450003; \(^2\)Department of Anesthesiology, Huangshi Central Hospital, Huangshi, Hubei 435000; \(^3\)Department of Ophthalmology, Third People’s Hospital of Jinan, Jinan, Shandong 250100; \(^4\)Department of Anesthesiology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan 450007, P.R. China

Received November 10, 2017; Accepted April 20, 2018

DOI: 10.3892/mmr.2018.8949

Abstract. Rapid proliferation is one of the critical characteristics of breast cancer. However, the underlying regulatory mechanism of breast cancer cell proliferation is largely unclear. The present study indicated that sevoflurane, one of inhalational anesthetics, could significantly suppress breast cancer cell proliferation by arresting cell cycle at G1 phase. Notably, the rescue experiment indicated that miR-203 was upregulated by sevoflurane and mediated the function of sevoflurane on suppressing the breast cancer cell proliferation. The present study indicated the function of the sevoflurane/miR-203 signaling pathway on regulating breast cancer cell proliferation. These results provide mechanistic insight into how the sevoflurane/miR-203 signaling pathway suppresses proliferation of breast cancer cells, suggesting the sevoflurane/miR-203 pathway may be a potential target in the treatment of breast cancer.

Introduction

Breast cancer is one of the most common cancers in women worldwide. Rapid proliferation ensures the growth and the further invasion of breast cancer (1). Determination of the regulatory mechanism of breast cancer proliferation, particularly the cell cycle regulation, is important for diagnosis earlier and clinical therapy.

Previous studies showed that sevoflurane, a common anesthetic, could repress the tumorigenesis of some types of cancers. For example, sevoflurane could inhibit the migration and invasion of glioma cells by upregulating the level of miR-637 (2). MMP-2 expression could be also repressed by sevoflurane to attenuate the migration of glioma cells (3). Sevoflurane inhibited hypoxia-induced growth and metastasis in lung cancer cells (4). Exposure to sevoflurane (1%) for 6 h promoted the proliferation of human colon cancer (5). These studies showed the inhibitory function of sevoflurane on cancer initiation and development. However, whether or how sevoflurane regulates the breast cancer growth and the downstream signaling pathway remain largely unknown.

MicroRNAs (miRNAs) are small non-coding RNAs, which regulate gene expression by binding to the 3-untranslated regions (3'UTRs) of mRNAs (6). miRNAs participate in regulating many biological processes including the embryonic development, initiation of many diseases (6-10). Increasing studies have showed that miRNAs affect the proliferation, metastasis, invasion of cancer cells. Additionally, the expression level of miRNAs can also determine the pathogenesis classification, diagnosis and prognosis of cancer (11-13). Among these miRNAs, miR-29 family have been reported to be the tumor regulator and biomarker (14,15). miR-106 promoted colorectal cancer cell migration and invasion by repressing the expression of DLC1 (16). Although more and more miRNAs were identified to be involved in cancer and other diseases, the particular roles of miRNA in different context of disease remain largely unknown. miR-203 has been also reported to be as the potential marker of the early detection of cervical cancer lymph node metastases. The low level of miR-203 was related to lymph node metastasis (17). A previous study showed that miR-203 repressed proliferation and induced apoptosis of colorectal cancer cells by post transcriptionally deregulating CPEB4 (18). However, prostate carcinoma patients with high miR-203 level showed lower average survival time than those with low miR-203 level (19). Although miR-203 showed different regulatory function in different cancers, miR-203 can be the critical regulator of some cancers and even the potential marker of diagnose. However, the function of miR-203...
on regulating the proliferation of breast cancer cells remains largely unknown.

In the present study we made the hypothesis that sevoflurane repressed the proliferation of breast cancer. In order to investigate the mechanism of proliferation regulation, we performed the cell cycle analysis and detected the miRNAs function and related regulatory signaling. This study may uncover the function of sevoflurane on regulating breast cancer cell proliferation and suggested the potential therapeutic target of miRNA for cancer prevention and treatment.

Materials and methods

Cell culture and sevoflurane treatment. Breast cancer cells were purchased from the Cell Bank Type Culture Collection of Chinese Academy of Sciences (CBTCCCAS; Shanghai, China) and cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) with fetal bovine serum (10%) (Gibco; Thermo Fisher Scientific, Inc.) at 37˚C, in a humidified atmosphere containing CO₂ (5%). The culture medium was added 100 U/ml of penicillin sodium (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA), and 100 mg/ml of streptomycin sulfate (Invitrogen; Thermo Fisher Scientific, Inc.). Cells were exposed to 2% sevoflurane for 6 h as previously described (5,20). 2% sevoflurane is clinically relevant and regulates the proliferation of human hepatocellular carcinoma cells (21). CO₂, O₂, and sevoflurane concentration was monitored by A Drager Vamos gas analyzer (Drager, Lübeck, Germany). The cells used for each experiments were culture in the 6 wells dish and seeded at the concentration of 1x10⁵/well.

Overexpression and inhibition of miRNA. Pre-miR-203, miRNA-203 inhibitor and the control miRNA were synthetic nucleic acids (Biotend, Shanghai, China). Pre-miRNAs can be processed by enzymes to become mature miRNAs. miRNA inhibitor has reverse complementary sequence of the miRNA. Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) was used for transfection of the pre-miRNA or inhibitor into cells which grown to approximately confluence (80%).

MTS proliferation assay. Proliferation was detected by CellTiter 96®. A Queuos One Solution Cell Proliferation Assay kit (Promega Corporation, Madison, WI, USA) was used to perform the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2(4-sul-fophenyl)-2H-tetrazo-lium (MTS) assay by following the instruction. The record absorbance at 490 nm was detected by microplate reader. We performed the detection every 24 h during 3 days.

Bromodeoxyuridine (BrdU) incorporation assay. Cells were seeded in 96-wells (2x10³ cells/well) in the culture medium with BrdU incubation. After 2 h, phosphate-buffered saline (PBS) solution with paraformaldehyde (PFA) (4%) was used to fix cells for 20 min. Cells were washed by PBS and treated by DNase for 20 min at room temperature. Then, BrdU primary antibody (Abcam, Cambridge, MA, USA) was added and incubated at 4°C for 12h. After washing by PBS, cells were incubated with secondary antibody at room temperature for 60 min. Cell nucleus were dyed by 4,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich; Merck KGaA). BrdU-positive cells were counted by microscope.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). RNAsio (Takara Bio, Inc., Inc., Otsu, Japan) was used for isolating total RNA. For reverse-transcription of miRNA, miRNA specific stem-loop reverse-transcription primer (RiboBio, China) was used. The amount of gene expression (2-ΔΔCt) was normalized to the endogenous nuclear RNA U6 using miRNA-specific primers (RiboBio Co., Ltd., Guangzhou, China). For mRNA RT-qPCR, cDNA was reverse-transcribed from mRNA by M-MLV Reverse Transcriptase (Takara) using random primers and oligo (dT) primers. The quantification of level of target gene expression (2^ΔΔCt) was normalized to the endogenous GAPDH mRNA (7.22). The reaction conditions of PCR were according to the SYBR-Green qPCR Mix instruction (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The primers sequences are as follows: Cyclin E1, PF, 5'-ACT CAACGTGCAAGCTCG-3', PR, 5'-GCTCAAGAAGT GCTGATCCC-3'; Cyclin D1, PF, 5'-CAAACTAGGACCG GCAGATT-3', PR, 5'-CATTGGAGGCCGATGGG-3'; P21, PF, 5'-TGGTCCTGACAGCAACCTACG-3', PR, 5'-AAA GTCAAGAATCTGCTGG-3'; P27, PF, 5'-TATTTGGG CCTCGGTACT-3', PR, 5'-TGACAGTGCTCCTTAT TCC-3'; RB1, PF, 5'-TTGGATCACGCAGATACAACCTT-3', PR, 5'-AGCCGACCCAAATAGACGAC-3'. The primers of miRNA RT-qPCR were purchased from the RiboBio Co., Ltd. The thermocycling condition for mRNA is as follows: For mRNA: 95°C for 30 sec followed by 40 cycles of 95°C for 10 sec, 60°C for 30 sec, 70°C for 30 sec. For miRNA: 95°C for 30 sec followed by 40 cycles of 95°C for 5 sec, 60°C for 20 sec, 70°C for 10 sec.

Western blot analysis. Proteins from MDA-MB-231 cells were lysed and then transferred onto PVDF membranes (Whatman, England). Then incubated the membranes with the primary antibodies diluted by TBST (Takoe, China) at room temperature for 2 h. The primary antibodies are as follows: Anti-GAPDH (ab9485, Abcam, USA), anti-cyclin E (ab135380, Abcam), anti-cyclin D1 (ab134175, Abcam), anti-P21 (ab109520, Abcam), anti-Rb1 (ab181616, Abcam). Then incubated the membranes with secondary antibodies diluted by TBST (Takoe) according to the primary antibodies at room temperature for 1 h. Protein signals were detected using enhanced chemiluminescence (ECL).

Statistical analyses. For statistical analyses, student's t-test or one way ANOVA with Boferroni's correction was used. The values were showed as the mean ± SD. P<0.05 was defined as statistically significant.

Results

Sevoflurane inhibits the proliferation of breast cancer cells. In order to determine the function of sevoflurane on breast cancer cells proliferation, MDA-MB-231 or MCF-7 cells were treated with sevoflurane (2%) for 6 h and cultured for another 24, 48 and 72 h without sevoflurane. The proliferation capacity was detected by MTS assay. The results showed that sevoflurane decreased proliferation of MDA-MB-231...
or MCF-7 cells (Fig. 1A). The BrdU incorporation assay in MDA-MB-231 cells treated with sevoflurane (2%) for 6 h and then cultured for another 24 h without sevoflurane was found showing decreased proliferation capacity (Fig. 1B). We further detected the cycle-related genes in MDA-MB-231 cells and found that the level of cyclin D, cyclin E, which have been reported to be the critical regulatory genes of G1 phase, were significantly downregulated. In contrary, the expression of Rb1, P21, P27, the cell cycle-inhibiting genes, were upregulated compared with control group on both mRNA and protein levels (Fig. 1C). Flow cytometry assay showed that proportion of cells at G1 phase was increased and cells at the S, G2/M phase was decreased after treating by sevoflurane in MDA-MB-231 cells (Fig. 1D).

miR-203 is upregulated by sevoflurane and repressed the proliferation of breast cancer cells. Using RT-qPCR, we detected that miR-203 could be upregulated in MDA-MB-231 cells treated with sevoflurane (2%) for 6 h and then cultured for another 24 h without sevoflurane were found showing decreased proliferation capacity (Fig. 1B). We further detected the cycle-related genes in MDA-MB-231 cells and found that the level of cyclin D, cyclin E, which have been reported to be the critical regulatory genes of G1 phase, were significantly downregulated. In contrary, the expression of Rb1, P21, P27, the cell cycle-inhibiting genes, were upregulated compared with control group on both mRNA and protein levels (Fig. 1C). Flow cytometry assay showed that proportion of cells at G1 phase was increased and cells at the S, G2/M phase was decreased after treating by sevoflurane in MDA-MB-231 cells (Fig. 1D).

miR-203 inhibitor rescues the effects of sevoflurane in breast cancer cells. In order to determine whether miR-203 actually mediated the function of sevoflurane, we performed the rescue experiment (Fig. 3). Results indicated that miR-203 inhibitor significantly attenuated the proliferation repression caused by sevoflurane treatment in both MDA-MB-231 (Fig. 3A and C) and MCF-7 cells (Fig. 3B). miR-203 inhibitor also resisted the effect of sevoflurane on the expression of cell cycle-related genes in MDA-MB-231 cells (Fig. 3D). Flow cytometry assay showed that, compared with MDA-MB-231 cells treated with sevoflurane, the increase of cells at G1 phase and the decrease of cells at the S and G2/M phase can be reversed by miR-203 inhibitor in MDA-MB-231 cells (Fig. 3E).
Figure 2. miR-203 was upregulated by sevoflurane and repressed the proliferation of breast cancer cells. (A) RT-qPCR showed the level of miR-203 was upregulated after sevoflurane treatment in MDA-MB-231 cells. (B) MTS assay showed the capacity of proliferation of MDA-MB-231 cells (left panel) and MCF-7 cells (right panel) transfected with miR-203 or miR-203 inhibitor. miR-203 means the pre-miR-203 mimics. miR-ctrl means the pre-miRNA control. (C) BrdU incorporation assay showed the effect of miR-203 in MDA-MB-231 cells. (D) RT-qPCR showed expression of cell cycle-related genes in MDA-MB-231 cells transfected with pre-miR-203 or pre-miRNA control. (E) Expression of cell cycle-related genes in MDA-MB-231 cells transfected with miR-203 inhibitor or control. (F) Flow cytometry assay showed the cell cycle change caused by transfection of pre-miR-203 or miR-203 inhibitor in MDA-MB-231 cells. *P<0.05, **P<0.01, ***P<0.001 vs. the corresponding control.

Figure 3. miR-203 inhibitor rescued the effects of sevoflurane in MDA-MB-231 cells. (A) MTS assay showed that miR-203 inhibitor blocked the proliferation of MDA-MB-231 cells. (B) MTS assay showed MCF-7 cell proliferation repression caused by sevoflurane. (C) BrdU incorporation assay in the rescue experiment showed inhibition of miR-203 blocked the effects of sevoflurane in MDA-MB-231 cells. (D) Expression of cell cycle-related genes was detected by RT-qPCR in the rescue experiment. (E) Flow cytometry assay showed that miR-203 inhibitor rescued the effects of sevoflurane in MDA-MB-231 cells. Data are shown as means ± SD (n=3-5). *P<0.05, **P<0.01, vs. the corresponding control.
Discussion

Breast cancer is the world's first serious malignant neoplasm which threaten the health of female, it had exceeded the cervical cancer and became the first factor of cancer deaths in women. Proliferation, invasion and metastasis are the important characteristic of breast cancer. Disclosing the underlying mechanism of breast cancer development will be helpful to find potential therapeutic approaches to treat breast cancer. Although sevoflurane is commonly used as an inhalational anesthetic during the surgery of cancer patients, evidences have demonstrated its effects on cell growth. A previous study reported that volatile anaesthetics, such as isoflurane, sevoflurane or desflurane, enhanced the metastasis-related cellular signaling including CXCR2 in ovarian cancer cells (24). Sevoflurane could induce the apoptosis of lung alveolar epithelial cells (25). Sevoflurane also was reported to regulate the expression of cyclin D1, but not p27Kip1 in the hippocampus (26). These studies suggested the complicated effects of sevoflurane on regulating the proliferation and cell cycle. It is significant to investigate the mechanism of regulatory effect of sevoflurane on different cells. In our study, we found that sevoflurane could significantly suppress the proliferation of MDA-MB-231 and MCF-7 breast cancer cells. Cells treated with sevoflurane arrested at the G1 phase. Our results showed that sevoflurane could be a potential therapeutic agent to prevent or treat breast cancer by regulating the cell cycle. Some other studies showed that sevoflurane possessed the opposite function, which suggested the complex effects of the sevoflurane on different cancer cells.

Among tumor-related miRNAs, miR-203 is one of the critical miRNAs that plays important roles in regulating proliferation of several types of cells. miR-203 reduced the PDGF-stimulated proliferation in human airway smooth muscle (HASM) cells (27), and formed the JNK-miR-203-p63 signaling to regulate keratinocyte proliferation and differentiation (28). miR-203 also plays important roles in cancerogenesis. miR-203 has been reported to be the tumor suppressor in osteosarcoma (29). miR-203 also directly targeted oncogene ADAM9 and long non-coding RNA HULC to inhibit the hepatocellular carcinoma cell proliferation and metastasis (30). In this study, we found that overexpression of miR-203 could suppress the proliferation and inhibition of miR-203 promoted the proliferation of MDA-MB-231 and MCF-7 breast cancer cells. Notably, miR-203 could be upregulated by sevoflurane treatment in breast cancer cells. The miR-203 inhibitor blocked the repression the proliferation of sevoflurane in breast cancer cells.

In this study, we uncovered the function of sevoflurane in regulating the breast cancer proliferation. Abnormal cell proliferation is most associated with influence of cell cycle regulation (31). The cell cycle was arrested at G1 phase, which is indicated by change of some important cell cycle-related genes expression.

It is the first time to determine the function and mechanism of sevoflurane in breast cancer cells. miR-203 is the downstream target of sevoflurane to mediate the proliferation and cell cycle. We will further study whether there are transcription factors involved in the expression of miR-203 regulated by sevoflurane. Additionally, we will also investigate the target genes of miR-203, which regulates cell cycle. We will also need further study about more similar types of breast cancers to validate the present results to confirm the mechanism of the miR-203 mediated the function of sevoflurane. Additionally, in vitro and in vivo studies will be conducted in order to validate the current results. In summary, we demonstrated a new functional role of sevoflurane/miR-203 signaling pathway on suppressing breast cancer cell proliferation and further confirmed the influence of cell cycle regulation of G1 phase and cell cycle-related genes expression.

Acknowledgements

Not applicable.

Funding

This research was supported by the Science and Technology Research Project of Henan Province (grant no. 142102310459), the Science and Technology Research Project of Henan Province (grant no. 162102310228) and the Medical Co construction Project of the Department of Health and Henan Province (grant no. 201701035).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

JYL and LY contributed to the study idea, analyzed the majority of the data, and wrote the initial draft of the paper. XG performed cell cycle analysis, GJ performed the cell culture and some of the BrdU experiments, QW was involved in the experimental operation of sevoflurane-treated cells and DL treated cells with sevoflurane. JLL performed the transfection experiments, QC designed the RT-qPCR primers and performed some of the RT-qPCR experiments, QS is one of the chief directors of this study and performed most of the statistical analysis and BL designed and guided the majority of the experiments and gave final approval of the manuscript. All authors discussed the results and contributed to the writing and revisions.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.
References


